Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sana In-Licenses BCMA CAR Construct from IASO/Innovent in $204 Million Deal

publication date: Jan 11, 2022

Sana Biotech, a Seattle company that creates engineered cells as medicines, acquired non-exclusive rights to a BCMA CAR construct from IASO Bio and Innovent in a $204 million agreement. Sana will have rights to use the construct in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. IASO Bio and Innovent will receive an unspecified upfront payment and up to $204 million in milestone payments for up to six products, plus royalties. Sana will develop gene and/or cell therapies for multiple myeloma, which is also the target for the IASO/Innovent CAR-T candidate. More details....

Stock Symbols: (NSDQ: SANA) (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.